Cohort profile for development of machine learning models to predict healthcare-related adverse events (Demeter): clinical objectives, data requirements for modelling and overview of data set for 2016-2018.

Journal: BMJ open
PMID:

Abstract

PURPOSE: In-hospital health-related adverse events (HAEs) are a major concern for hospitals worldwide. In high-income countries, approximately 1 in 10 patients experience HAEs associated with their hospital stay. Estimating the risk of an HAE at the individual patient level as accurately as possible is one of the first steps towards improving patient outcomes. Risk assessment can enable healthcare providers to target resources to patients in greatest need through adaptations in processes and procedures. Electronic health data facilitates the application of machine-learning methods for risk analysis. We aim, first to reveal correlations between HAE occurrence and patients' characteristics and/or the procedures they undergo during their hospitalisation, and second, to build models that allow the early identification of patients at an elevated risk of HAE.

Authors

  • Svetlana Artemova
    Public Health Department, Clinical Investigation Center-Technological, Innovation, INSERM CIC1406, CHU Grenoble Alpes, Université Grenoble Alpes, Grenoble, France.
  • Ursula von Schenck
    Life Science Analytics, Elsevier BV, Berlin, Germany.
  • Rui Fa
    The Francis Crick Institute, London, United Kingdom.
  • Daniel Stoessel
    Life Science Analytics, Elsevier BV, Berlin, Germany.
  • Hadiseh Nowparast Rostami
    Life Science Analytics, Elsevier BV, Berlin, Germany.
  • Pierre-Ephrem Madiot
    Digital Services Management, CHU Grenoble Alpes, Grenoble, France.
  • Jean-Marie Januel
    TIMC, CNRS UMR5525, Université Grenoble Alpes, Grenoble, France.
  • Daniel Pagonis
    Public Health Department, CHU Grenoble Alpes, Grenoble, France.
  • Caroline Landelle
    TIMC, CNRS UMR5525, Université Grenoble Alpes, Grenoble, France.
  • Meghann Gallouche
    TIMC, CNRS UMR5525, Université Grenoble Alpes, Grenoble, France.
  • Christophe Cancé
    Public Health Department, INSERM CIC1406, CHU Grenoble Alpes, Grenoble, France.
  • Frederic Olive
    Public Health Department, CHU Grenoble Alpes, Grenoble, France.
  • Alexandre Moreau-Gaudry
    Univ. Grenoble Alpes, CNRS, Grenoble INP, TIMC-IMAG, 38000, Grenoble, France.
  • Sigurd Prieur
    Life Science Analytics, Elsevier BV, Berlin, Germany.
  • Jean-Luc Bosson
    Clinical Investigation Center, Grenoble University Hospital, Grenoble, France.